WEDNESDAY, 13th March 2019 COMMENCING 10:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY, CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Appraisal 1: Limited Submission (PAS) dasatinib (Sprycel®) for the treatment of paediatric patients weighing > 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib

6. Appraisal 2: Limited Submission (PAS) ataluren (Translarna®) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years to 5 years old

To protect commercial confidentiality the following appraisals will be held in private

7. Chairman’s report (verbal update)

8. Therapeutic Priorities and CEPP Summary 2019-2020

Date of next meeting – Wednesday, 10th April 2019 in Cardiff

Enclosure

1/AWMSG/0319

Appendices

2/AWMSG/0319

Appendices

3/AWMSG/0319

Appendices

4/AWMSG/0319